On February 24, 2026 AtomVie Global Radiopharma (AtomVie), a global leading radiopharmaceutical CDMO, reported that it has supplied the successful dosing of the first patient in Radiopharm Theranostics’ First-in-Human Phase 1/2a clinical study of 177Lu‑BetaBart (RV‑01) by providing GMP manufacturing and distribution services for the radiotherapeutic drug product, after successfully developing and qualifying the radiolabeling process and analytical methods using a phase-appropriate approach that expedited IND filing.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Phase 1/2a clinical study is designed as a dose-escalation and expansion trial evaluating the safety, biodistribution, radiation dosimetry, and preliminary anti-tumor activity of 177Lu‑BetaBart, while also determining the recommended dose for future studies. 177Lu-BetaBart (RV‑01) is a 177Lutetium‑conjugated monoclonal antibody engineered to target the 4Ig isoform of B7‑H3, an immune checkpoint molecule overexpressed across multiple solid tumor types.

"Enabling the first patient dose of 177Lu-BetaBart reflects what matters most to us, ensuring that high‑quality radiopharmaceuticals are manufactured, released, and delivered on time so patients can access innovative therapies without delay," said Bruno Paquin, Chief Executive Officer of AtomVie. "Our team is deeply focused on operational excellence and reliability, supporting our partners from early clinical development through global supply."

"Dosing the first patient in the Phase 1/2a clinical study of 177Lu‑BetaBart represents an important milestone for Radiopharm Theranostics," said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. "We appreciate AtomVie’s manufacturing expertise and commitment to quality as we advance BetaBart for patients with aggressive and difficult‑to‑treat solid tumors."

About BetaBart (RV-01)

RV-01 is the first radiopharmaceutical therapeutic agent developed by Radiopharm Ventures, the Joint Venture formed between Radiopharm Theranostics and The University of Texas MD Anderson Cancer Center. 177Lu-BetaBart is a 177Lutetium-conjugated therapeutic that targets B7-H3, an immune checkpoint molecule that is overexpressed in several tumor types. Multiple preclinical studies with BetaBart have shown tumor shrinkage and prolonged survival in animals treated with the radiotherapeutic agent.

About the Phase 1/2a Clinical Trial

The FIH Phase 1/2a study (NCT07189871) is designed to establish the safety profile, biodistribution, pharmacokinetics, and radiation dosimetry of 177Lu-Betabart . The study aims to enroll 61 eligible participants who have a documented history of histopathologically confirmed castrate resistant prostate cancer, colorectal cancer, non-small cell lung cancer, small cell lung cancer, head and neck squamous cell cancer, ovarian cancer, cervical cancer, endometrial cancer, triple negative breast cancer, or esophageal squamous cell carcinoma.

(Press release, Radiopharm Theranostics, FEB 24, 2026, View Source [SID1234662946])

On February 24, 2026 Hoth Therapeutics, Inc. (NASDAQ: HOTH) reported a significant expansion of its CLEER-001 Phase 2a clinical trial with the addition of Regis Clinical Research as a new enrolling site. Located in Miami, Florida, Regis joins the growing CLEER-001 investigational site network as surging patient demand outpaces capacity at existing sites — a direct reflection of the compelling early clinical results HT-001 has produced and the desperate unmet need it addresses.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

For the estimated 200,000 Americans who begin EGFR Inhibitor cancer therapy each year, the skin toxicities that accompany treatment are not a minor inconvenience. They are severe, often disfiguring rashes, lesions, and unrelenting itch that force up to one-third of patients to reduce or discontinue the chemotherapy keeping them alive. Today, those patients have no FDA-approved treatment option. HT-001 is designed to change that — and the data so far suggests it can.

Positive Signal

The interim CLEER-001 data is generating physician and patient interest that drives enrollment expansions like today’s announcement:

100% of open-label cohort patients achieved the primary efficacy endpoint — an ARIGA rash severity score of ≤1 — by week six
Zero patients required dose reduction or discontinuation of their life-saving EGFRi cancer therapy while on HT-001
Over 65% of patients reported meaningful reductions in pain and itching
Zero dose-limiting toxicities observed across the entire trial to date
At the American Academy of Dermatology Annual Meeting, a case study demonstrated complete lesion and symptom resolution after just one week of twice-daily application in a metastatic breast cancer patient
For a patient population that currently has no targeted treatment, results like these represent a potential paradigm shift in how oncologists can manage one of the most common and quality-of-life-destroying side effects in all of cancer care.

A New Site, A New Market, A Growing Network

Regis Clinical Research brings IRB-approved, FDA-compliant research infrastructure and a new South Florida patient population to the CLEER-001 network. For Hoth, it means faster enrollment, a faster path to a complete data set, and a faster road to the regulatory milestones that matter.

"The addition of Regis Clinical Research is a direct response to the acceleration we are seeing in enrollment demand," said Robb Knie, Chief Executive Officer of Hoth Therapeutics. "The data speaks for itself. Patients and oncologists are taking notice — and we are building the infrastructure to meet that demand and deliver the full clinical readout this program deserves."

Patients and referring physicians may visit regisclinical.com or call +1 (305) 546-3952 to learn more about participation in the CLEER-001 trial.

(Press release, Hoth Therapeutics, FEB 24, 2026, View Source [SID1234662945])

On February 24, 2026 Nektar Therapeutics (Nasdaq: NKTR) reported that company management will be participating in the TD Cowen 46th Annual Health Care Conference taking place March 2-4, 2026 in Boston and the 2026 Jefferies Biotech on the Beach Summit taking place March 9-11, 2026 in Miami.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TD Cowen 46th Annual Health Care Conference in Boston on Wednesday, March 4, 2026 – webcast of the presentation to be available at 9:10 a.m. Eastern Time / 6:10 a.m. Pacific Time – link here
2026 Jefferies Biotech on the Beach Summit in Miami – March 9-11, 2026 – company management to be available for one-on-one meetings
The presentation will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website: View Source A replay of the presentation will be available for 30 days.

If you would like to request a one-on-one meeting with company management during the conferences, please reach out to your respective representative.

(Press release, Nektar Therapeutics, FEB 24, 2026, View Source [SID1234662944])

On February 24, 2026 AbbVie (NYSE: ABBV) reported it will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026. Management will participate in a fireside chat at 10:10 a.m. Central Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be accessible through AbbVie’s Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.

(Press release, AbbVie, FEB 24, 2026, View Source [SID1234662943])

On February 24, 2026 Elephas Biosciences Corporation (Elephas), a private company that has developed an innovative live tissue platform for immunotherapy response prediction, reported a new research partnership with the University of Louisville that will evaluate the impact of a combination therapy of surgical intervention and immunotherapy in three different cancers, including colorectal, liver, and pancreatic. As part of the collaboration, the University of Louisville will be analyzing live tumor specimens on the Elephas Live Platform in conjunction with multiple Investigator Initiated Trials.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

With only one in five cancer patients benefiting from immunotherapy, there is a critical need for real‑time functional response data. The Elephas Live Platform measures how an intact, live tumor sample responds to therapy in real time. The company is executing a global commercialization strategy and expanding collaborations with groups focused on advancing immunotherapy success rates.

"I have been working closely with Elephas for several years and I am excited to integrate their platform into our research laboratory to advance a more personalized approach to cancer care," shared Robert Martin, M.D., Ph.D., Vice Chair for the Department of Surgery and Professor/Director of Surgical Oncology Research Laboratory of the University of Louisville. "By evaluating how an individual patient’s live tumor responds to immunotherapy in real time—particularly in conjunction with surgical intervention—we can move beyond population-based treatment strategies toward truly individualized therapeutic decision-making. Advanced stage colorectal, liver, and pancreatic cancers remain extraordinarily challenging to treat, and precision tools that help tailor therapy to each patient’s tumor biology are essential to improving outcomes and ultimately enhancing the lives of patients."

"We are honored to partner with Dr. Martin and the team at the University of Louisville to continue exploring the ways we believe our platform can help to inform better treatment options," said Maneesh Arora, Elephas Founder and CEO. "Progress in oncology depends on strong collaborations that bring together clinical expertise and advanced technology. These studies can bring meaningful improvements in patient cancer care."

(Press release, University of Louisville, FEB 24, 2026, View Source [SID1234662942])